Talquetamab Safety Profile in Relapsed/Refractory MM
The panel discusses the safety profile of talquetamab for patients with relapsed/refractory multiple myeloma.
This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Compared with BCMA-directed therapies, talquetamab shows less pronounced infection risk, likely due to the continuous dosing of bispecific antibodies that constantly challenges the immune system vs the transient effects of chimeric antigen receptor T-cell therapy. However, talquetamab’s targeting of GPRC5D expressed on gastrointestinal and skin tissues causes unique toxicities such as dysgeusia, dermatologic changes, and nail abnormalities. Compared with grade 3 or higher infection rates of 40% or more with BCMA therapies, grade 3 or higher infection rates areless than 20% with talquetamab. Other distinctive toxicities may include hair changes and testicular effects, though manifestations are unclear. Overall, talquetamab demonstrates efficacy comparability to BCMA-directed treatments but a differentiated safety profile.
Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.
